文献速递糖尿病

全基因组荟萃分析发现磺脲类药物血糖反应相关遗传变异

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.
PubMed 文献 · Diabetes Care · 2021-10-04

本研究纳入5485例接受磺脲类治疗的欧洲2型糖尿病患者,估计磺脲类反应遗传率为37±11%,全基因组关联分析发现GXYLT1和SLCO1B1基因附近两个位点与HbA1c降低相关,并观察到他汀类药物与SLCO1B1基因型的显著交互作用。

要点

  • 磺脲类血糖反应具有遗传性,估计遗传率为37±11%。
  • GXYLT1附近rs1234032的C等位与HbA1c降低较少相关。
  • SLCO1B1内含子rs10770791的C等位与他汀交互影响HbA1c降低。

核心结论

  • 识别出GXYLT1和SLCO1B1附近与磺脲类血糖反应相关的遗传位点,并发现他汀与SLCO1B1基因型的药物-药物-基因交互作用。

研究设计与样本

  • MetGen Plus和DIRECT联盟 initiative,纳入5485例接受磺脲类治疗的欧洲2型糖尿病患者,来自欧洲和北美6个转诊中心。
  • 采用广义限制最大似然法估计遗传率,并进行全基因组关联研究及荟萃分析,辅以格列吡嗪急性激发试验、cis eQTL和细胞功能验证。

主要发现

  • 磺脲类反应遗传率为37±11%(mean±SEM)。
  • rs1234032(GXYLT1附近)C等位与HbA1c降低少0.14%(1.5 mmol/mol)相关,P=2.39×10-8。
  • rs10770791(SLCO1B1内含子)C等位与HbA1c降低多0.11%(1.2 mmol/mol)相关,P=4.80×10-8。
  • 在非他汀使用者中,rs10770791 C等位纯合子HbA1c绝对降低0.48±0.12%(5.2±1.26 mmol/mol),相当于启动DPP-4抑制剂的效应。

关键数值与推荐

  • 全基因组显著性阈值P<5×10-8。
  • rs1234032 C等位与HbA1c降低少0.14%(1.5 mmol/mol),P=2.39×10-8。
  • rs10770791 C等位与HbA1c降低多0.11%(1.2 mmol/mol),P=4.80×10-8。
  • 他汀使用与SLCO1B1基因型交互作用P=0.001。

临床怎么用

  • 遗传数据可嵌入临床记录,未来或可指导磺脲类降糖药处方。
  • 使用他汀的患者需考虑SLCO1B1基因型对磺脲类血糖反应的影响。

局限性

  • 研究人群为欧洲白人2型糖尿病患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sulfonylureas, the first available drugs for the management of type 2 diabetes, remain widely prescribed today. However, there exists significant variability in glycemic response to treatment. We aimed to establish heritability of sulfonylurea response and identify genetic variants and interacting treatments associated with HbA1c reduction. RESEARCH DESIGN AND METHODS: As an initiative of the Metformin Genetics Plus Consortium (MetGen Plus) and the DIabetes REsearCh on patient straTification (DIRECT) consortium, 5,485 White Europeans with type 2 diabetes treated with sulfonylureas were recruited from six referral centers in Europe and North America. We first estimated heritability using the generalized restricted maximum likelihood approach and then undertook genome-wide association studies of glycemic response to sulfonylureas measured as HbA1c reduction after 12 months of therapy followed by meta-analysis. These results were supported by acute glipizide challenge in humans who were naïve to type 2 diabetes medications, cis expression quantitative trait loci (eQTL), and functional validation in cellular models. Finally, we examined for possible drug-drug-gene interactions. RESULTS: After establishing that sulfonylurea response is heritable (mean ± SEM 37 ± 11%), we identified two independent loci near the GXYLT1 and SLCO1B1 genes associated with HbA1c reduction at a genome-wide scale (P < 5 × 10-8). The C allele at rs1234032, near GXYLT1, was associated with 0.14% (1.5 mmol/mol), P = 2.39 × 10-8), lower reduction in HbA1c. Similarly, the C allele was associated with higher glucose trough levels (β = 1.61, P = 0.005) in healthy volunteers in the SUGAR-MGH given glipizide (N = 857). In 3,029 human whole blood samples, the C allele is a cis eQTL for increased expression of GXYLT1 (β = 0.21, P = 2.04 × 10-58). The C allele of rs10770791, in an intronic region of SLCO1B1, was associated with 0.11% (1.2 mmol/mol) greater reduction in HbA1c (P = 4.80 × 10-8). In 1,183 human liver samples, the C allele at rs10770791 is a cis eQTL for reduced SLCO1B1 expression (P = 1.61 × 10-7), which, together with functional studies in cells expressing SLCO1B1, supports a key role for hepatic SLCO1B1 (encoding OATP1B1) in regulation of sulfonylurea transport. Further, a significant interaction between statin use and SLCO1B1 genotype was observed (P = 0.001). In statin nonusers, C allele homozygotes at rs10770791 had a large absolute reduction in HbA1c (0.48 ± 0.12% [5.2 ± 1.26 mmol/mol]), equivalent to that associated with initiation of a dipeptidyl peptidase 4 inhibitor. CONCLUSIONS: We have identified clinically important genetic effects at genome-wide levels of significance, and important drug-drug-gene interactions, which include commonly prescribed statins. With increasing availability of genetic data embedded in clinical records these findings will be important in prescribing glucose-lowering drugs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dawed AY, Yee SW, Zhou K, et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care. 2021. PMID: 34607834. doi:10.2337/dc21-1152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。